Pirprofen (Rengasil) in the treatment of juvenile rheumatoid arthritis. A segment I study.
Thirty-two patients with JRA were enrolled in a 4-wk open-labeled, non-controlled multicentre trial of pirprofen. An initial dose of about 300 mg/m2/d (range 250-330) was gradually increased to a maximum of 600 mg/m2/d (range 413-761). The medication was provided as an aqueous suspension (10 mg/ml), and was given 4 times/d. Efficacy analysis showed significant decreases occurred in the DMS, travel time, grip strength, and the severity of swelling score (in all cases p less than 0.05 based on the paired Student t test, 2-tailed). Nineteen patients reported a total of 27 adverse experiences; 6 of which were attributable to pirprofen. At the study dosages used pirprofen seems to be very similar in efficacy and safety to other nonsteroidal antiinflammatory drugs investigated in children with JRA.
D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D010666:Phenylpropionates / Q000627:therapeutic use*
D010666:Phenylpropionates; C008924:pirprofen